Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

NCT04512534

Peripheral T-cell Lymphoma

RECRUITING PHASE2

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

NCT04831710

Angioimmunoblastic T-cell Lymphoma

UNKNOWN PHASE2

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

NCT06793956

Extranodal Natural Killer/T Cell Lymphoma

RECRUITING PHASE1

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

NCT07139353

Peripheral T Cells Lymphoma (PTCL)

NOT_YET_RECRUITING PHASE1/PHASE2

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT04329130

Relapsed or Refractory Peripheral T-cell Lymphoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-arm phase 2 study with fixed does of combined Sintilimab and Chidamide regimen. This regimen is repeated every 21 days. Sintilimab (200mg) is administered intravenously on day 1 of every cycle. Chidamide is used 20mg twice per week continuously. From the beginning of the trial, sindilimab will be used for 96 weeks, until disease progress, intolerable toxicity or patient/investigator discretion. Patients will continue to receive Chidamide treatment until disease progression, unacceptable toxicity, or patient/investigator discretion.

The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment. The patients who achieve complete remission (CR), partial remission (PR), and stable disease (SD) will receive further treatment. The patients with progressed disease (PD) will be continue on the treatment and reassess after 4-8 weeks to rule out false progression. On confirmation of PD , patients will be withdrawn from the trial and receive salvage regimens.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous T-cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chidamide plus Sintilimab

Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.

Group Type EXPERIMENTAL

Sintilimab

Intervention Type DRUG

200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment

Chidamide

Intervention Type DRUG

20mg po per week continuously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sintilimab

200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment

Intervention Type DRUG

Chidamide

20mg po per week continuously

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologically confirmed cutaneous T-cell lymphoma according World Health Organization (WHO) classification.
* ECOG≤2
* Patients with measurable lesions, with or without extra-dermal lesions, clinical stage of IIB-IVB.
* Patients received at least one systemic treatment previously and achieved no remission or relapsed after first-line treatment.
* Absolute neutrophil count (ANC）≥0.75×109/L，platelet (PLT) ≥ 50×109/L，hemoglobin (HGB）≥ 80 g/L
* Thyroid stimulating hormone (TSH) within normal range

Exclusion Criteria

* Pre-existing uncontrolled active infection
* Alanine aminotransferase (ALT) \>3 times upper limit of normal (ULN), total bilirubin (TBIL) \>1.5 times ULN, serum creatinine \>1.5 times ULN
* Patients with clinically significant QT interval prolongation (male \> 450ms, female \> 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), acute coronary syndrome (ACS) within 1 year, congestive heart failure (CHF), and symptomatic coronary heart disease.
* Patients who have received organ transplantation or hematopoietic stem cell transplantation.
* Active bleeding or recent thrombotic disease
* Patients with known interstitial lung disease
* Patients with active autoimmune disease or history of autoimmune disease in the past 2 years
* Patients with CNS involvement
* Pregnant or lactating women
* History of mental illness

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No